Step by Step

2025-01-07 - Medical Grand Rounds: Bad bugs, new drugs: Progress and challenges in the fight against antimicrobial resistance

INTRODUCTION

ABIM MOC Activity ID

1/7/2025 - Medical Grand Rounds: Bad bugs, new drugs: Progress and challenges in the fight against antimicrobial resistance

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

Describe the burden of antimicrobial resistance in 2025
Identify the benefits of newly-approved beta-lactam agents for CRE
Outline the preferred antibiotic agents for treatment of MDR Pseudomonas infections

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested Additional Reading:

Pham TM, et al. Lancet ID 2024 Dec;24(12):1333. Available at: https://pubmed.ncbi.nlm.nih.gov/39151443/
Shields RK, et al. Lancet ID 2024 (ahead of print). Available at: https://pubmed.ncbi.nlm.nih.gov/39701120/
Tamma PD, et al. Clinical Infect Dis 2024 (online ahead of print). Available at: https://pubmed.ncbi.nlm.nih.gov/39108079/

Joint Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™.Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:

Ryan Shields, PharmD, MS — Associate Professor of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine
Dr. Shields receives grant/research support from Merck, Shionogi, Innoviva, Melinta, and Roche. Dr. Shields is a consultant for Merck, Shionogi, Melinta, bioMerieux, AbbVie, GlaxoSmithKline, and Venatorx.

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.